Search

Your search keyword '"Yoshihara, Satoshi"' showing total 125 results

Search Constraints

Start Over You searched for: Author "Yoshihara, Satoshi" Remove constraint Author: "Yoshihara, Satoshi" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
125 results on '"Yoshihara, Satoshi"'

Search Results

1. Timescales of Solar System Formation Based on Al-Ti Isotope Correlation by Supernova Ejecta

2. Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG: ACUTE MYELOID LEUKEMIA

3. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients

4. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

5. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia

7. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission

8. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

9. Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation

10. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

12. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial

14. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

16. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

17. Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission

18. Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry

19. Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation

20. Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.

22. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

23. RhD mismatch does not affect haematopoietic recovery, graft‐versus‐host disease and survival in allogeneic haematopoietic cell transplantation: A Japanese registry‐based study

24. Individualized rabbit anti‐thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high‐risk hematologic malignancy: Exposure–response analysis and population pharmacokinetics simulations

25. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission

26. 本邦における造血幹細胞採取等のアフェレーシスの実態調査

28. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy

30. A case of non‐Hodgkin lymphoma of the upper gingiva with minimal residual disease detected in cryopreserved ovarian tissue: A case report.

31. P424: LANDSCAPE OF CHROMATIN ACCESSIBILITY IN ACUTE MYELOID LEUKEMIA

32. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

33. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

34. Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

35. Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

37. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

38. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

39. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone

40. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

41. Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

42. ESTABLISHMENT OF A SUSTAINABLE CAR T-CELL THERAPY OPERATION SYSTEM BY UTILIZING THE ALREADY-EXISTING STRUCTURE AT THE BLOOD TRANSFUSION DIVISION

43. Relationship between Pharmacokinetics of Rabbit Anti-Thymocyte Globulin and Acute Graft Versus Host Disease in Haploidentical Hematopoietic Stem Cell Transplantation

45. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

46. Cytomegalovirus-Seronegative Plus Leukoreduced Blood Products Are Still Superior to Only Leukoreduced Products in Preventing Transfusion-Transmitted Cytomegalovirus Infection

48. 375 - Relationship between Pharmacokinetics of Rabbit Anti-Thymocyte Globulin and Acute Graft Versus Host Disease in Haploidentical Hematopoietic Stem Cell Transplantation

49. Monocyte or white blood cell counts and β2microglobulin predict the durable efficacy of daratumumab with lenalidomide

50. Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

Catalog

Books, media, physical & digital resources